Every year about 57,600 Americans will be diagnosed with pancreatic cancer and about 47,000 will die. It’s the 3rd leading cause of cancer-related death in the U.S. The Pancreatic Cancer Collective’s PSAs aim to raise awareness about treatment options to increase diversity in pancreatic cancer clinical trials to ensure patients of all racial and ethnic backgrounds benefit equally from the potential of cancer treatments.